Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Annals of Oncology|2019Cited by 475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancersChunhong Hu, Fang Wu, Chao Deng et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 77
Assessment of Vascularity in Hepatic Alveolar Echinococcosis: Comparison of Quantified Dual-Energy CT with Histopathologic ParametersYi Jiang, Wenya Liu|PLoS ONE|2016Cited by 33
Older Age Is Associated with Decreased Levels of VDR, CYP27B1, and CYP24A1 and Increased Levels of PTH in Human Parathyroid GlandsYi Jiang, Zhongjian Xie|International Journal of Endocrinology|2020Cited by 18